Aytu BioPharma Q1 revenue beats expectations

Reuters11-14

<a href="https://laohu8.com/S/AYTUZ">Aytu BioPharma</a> Q1 revenue beats expectations

Overview

Aytu fiscal Q1 2026 revenue of $13.9 mln beats analyst expectations
Net income for fiscal Q1 2026 rises to $2.0 mln from $1.5 mln year ago
Adjusted EBITDA beats expectations, reflecting EXXUA launch investments

Outlook

Aytu BioPharma on track to launch EXXUA in Q4 2025 for MDD market

Result Drivers

ADHD PORTFOLIO - Revenue increased 10% excluding last year's rebate, driven by price increases and improved gross-to-nets
PEDIATRIC PORTFOLIO - Revenue decline due to manufacturing delays and reduced marketing emphasis
EXXUA LAUNCH INVESTMENTS - Adjusted EBITDA impacted by investments for EXXUA launch

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q1 Revenue	Beat	$13.89 mln	$12.40 mln (2 Analysts)
Q1 Net Income		$1.97 mln
Q1 Adjusted EBITDA	Beat	-$600,000	-$1.34 mln (2 Analysts)
Q1 Gross Profit		$9.19 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Aytu Biopharma Inc is $8.00, about 74.3% above its November 12 closing price of $2.06

Press Release: ID:nACS5xzx9a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2583514491?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 05:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583514491","market":"us","top_or_hot":-1,"title":"Aytu BioPharma Q1 revenue beats expectations","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/AYTUZ\">Aytu BioPharma</a> Q1 revenue beats expectations</title></head><body><p><span>Overview</span></p><ul><li><p>Aytu fiscal Q1 2026 revenue of $13.9 mln beats analyst expectations</p></li><li><p>Net income for fiscal Q1 2026 rises to $2.0 mln from $1.5 mln year ago</p></li><li><p>Adjusted EBITDA beats expectations, reflecting EXXUA launch investments</p></li></ul><p><span>Outlook</span></p><ul><li><p>Aytu BioPharma on track to launch EXXUA in Q4 2025 for MDD market</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>ADHD PORTFOLIO - Revenue increased 10% excluding last year's rebate, driven by price increases and improved gross-to-nets</p></li><li><p>PEDIATRIC PORTFOLIO - Revenue decline due to manufacturing delays and reduced marketing emphasis</p></li><li><p>EXXUA LAUNCH INVESTMENTS - Adjusted EBITDA impacted by investments for EXXUA launch</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q1 Revenue</p></td><td><p>Beat</p></td><td><p>$13.89 mln</p></td><td><p>$12.40 mln (2 Analysts)</p></td></tr><tr><td><p>Q1 Net Income</p></td><td></td><td><p>$1.97 mln</p></td><td></td></tr><tr><td><p>Q1 Adjusted EBITDA</p></td><td><p>Beat</p></td><td><p>-$600,000</p></td><td><p>-$1.34 mln (2 Analysts)</p></td></tr><tr><td><p>Q1 Gross Profit</p></td><td></td><td><p>$9.19 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Aytu Biopharma Inc is $8.00, about 74.3% above its November 12 closing price of $2.06</p></li></ul><p>Press Release: <span>ID:nACS5xzx9a</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aytu BioPharma Q1 revenue beats expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAytu BioPharma Q1 revenue beats expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-14 05:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/AYTUZ\">Aytu BioPharma</a> Q1 revenue beats expectations</title></head><body><p><span>Overview</span></p><ul><li><p>Aytu fiscal Q1 2026 revenue of $13.9 mln beats analyst expectations</p></li><li><p>Net income for fiscal Q1 2026 rises to $2.0 mln from $1.5 mln year ago</p></li><li><p>Adjusted EBITDA beats expectations, reflecting EXXUA launch investments</p></li></ul><p><span>Outlook</span></p><ul><li><p>Aytu BioPharma on track to launch EXXUA in Q4 2025 for MDD market</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>ADHD PORTFOLIO - Revenue increased 10% excluding last year's rebate, driven by price increases and improved gross-to-nets</p></li><li><p>PEDIATRIC PORTFOLIO - Revenue decline due to manufacturing delays and reduced marketing emphasis</p></li><li><p>EXXUA LAUNCH INVESTMENTS - Adjusted EBITDA impacted by investments for EXXUA launch</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q1 Revenue</p></td><td><p>Beat</p></td><td><p>$13.89 mln</p></td><td><p>$12.40 mln (2 Analysts)</p></td></tr><tr><td><p>Q1 Net Income</p></td><td></td><td><p>$1.97 mln</p></td><td></td></tr><tr><td><p>Q1 Adjusted EBITDA</p></td><td><p>Beat</p></td><td><p>-$600,000</p></td><td><p>-$1.34 mln (2 Analysts)</p></td></tr><tr><td><p>Q1 Gross Profit</p></td><td></td><td><p>$9.19 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Aytu Biopharma Inc is $8.00, about 74.3% above its November 12 closing price of $2.06</p></li></ul><p>Press Release: <span>ID:nACS5xzx9a</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AYTU","symbol_name":"Aytu BioScience, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL1N3WP185:1","article_id":"2583514491","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583514491","pubTimestamp":1763068457,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Aytu BioPharma Q1 revenue beats expectationsOverviewAytu fiscal Q1 2026 revenue of $13.9 mln beats analyst expectationsNet income for fiscal Q1 2026 rises to $2.0 mln from $1.5 mln year agoAdjusted EB","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AYTU":"Aytu BioScience, Inc.","BK4007":"制药"},"translate_title":"Aytu BioPharma第一季度收入超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AYTU":0.9},"content_text":"Aytu BioPharma Q1 revenue beats expectationsOverviewAytu fiscal Q1 2026 revenue of $13.9 mln beats analyst expectationsNet income for fiscal Q1 2026 rises to $2.0 mln from $1.5 mln year agoAdjusted EBITDA beats expectations, reflecting EXXUA launch investmentsOutlookAytu BioPharma on track to launch EXXUA in Q4 2025 for MDD marketResult DriversADHD PORTFOLIO - Revenue increased 10% excluding last year's rebate, driven by price increases and improved gross-to-netsPEDIATRIC PORTFOLIO - Revenue decline due to manufacturing delays and reduced marketing emphasisEXXUA LAUNCH INVESTMENTS - Adjusted EBITDA impacted by investments for EXXUA launchKey DetailsMetricBeat/MissActualConsensus EstimateQ1 RevenueBeat$13.89 mln$12.40 mln (2 Analysts)Q1 Net Income$1.97 mlnQ1 Adjusted EBITDABeat-$600,000-$1.34 mln (2 Analysts)Q1 Gross Profit$9.19 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the pharmaceuticals peer group is \"buy\"Wall Street's median 12-month price target for Aytu Biopharma Inc is $8.00, about 74.3% above its November 12 closing price of $2.06Press Release: ID:nACS5xzx9aFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583514491","isCrawlerRequest":true}